Globalspace Technologies has notified the BSE of an upcoming Board of Directors meeting scheduled for Friday, May 15, 2026. The meeting will be conducted through video conferencing mode and is deemed to be held at the company's registered office. The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The primary agenda for the upcoming board meeting is the consideration and approval of the company's audited financial results. The following key item is scheduled for deliberation:

Trading Window Closure

In connection with the upcoming results announcement, Globalspace Technologies has also informed that the trading window for designated persons and their immediate relatives has been closed with effect from the close of trading hours on April 01, 2026. The trading window will remain closed and is set to reopen 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. This measure has been implemented to ensure compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, including amendments thereto.

Signatory Details

The board meeting intimation has been signed by Krishna Murari Singh, Managing Director of Globalspace Technologies, on May 11, 2026. The company is registered under CIN: L64201MH2010PLC211219, and its registered office is located at Office No. 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Mahape, Navi Mumbai 400710.

GlobalSpace Technologies has announced the launch of PATGPT, a groundbreaking pharmaceutical-specific Large Language Model (LLM) platform, marking a significant milestone in the company's journey towards becoming a leader in AI-driven healthcare solutions.

Hybrid Training Model

PATGPT operates on an innovative hybrid model, with 50% of the training completed by GlobalSpace using pharmaceutical datasets. The remaining 50% will be trained using proprietary data from pharmaceutical companies within their secure cloud environments. This approach positions PATGPT as both a product and a customized LLM training service, allowing pharmaceutical companies to build organization-specific AI intelligence securely.

Initial Focus and Future Applications

In its initial phase, PATGPT will concentrate on optimizing four key areas:

1. Sales
2. Marketing
3. Inventory
4. Distribution

The company has outlined an ambitious roadmap for future applications, including:

• Research and Development (R&D)
• Clinical trials
• Pharmacovigilance
• Regulatory submissions

Strategic Importance

Tania Mazumdar, Executive Director of GlobalSpace Technologies, emphasized the strategic importance of this launch, stating, "The launch of PATGPT marks a significant milestone in GlobalSpace's journey towards becoming a leader in AI-driven healthcare solutions."

New Revenue Streams

The introduction of PATGPT is expected to create new revenue streams for GlobalSpace Technologies through:

1. Product licensing
2. AI training services

About GlobalSpace Technologies Ltd

GlobalSpace Technologies Ltd is a listed digital solutions company that focuses on the healthcare and pharmaceutical sectors. The company provides Software as a Service (SaaS) platforms and AI-powered solutions that enable pharmaceutical companies to:

• Digitize sales force operations
• Strengthen compliance
• Enhance engagement with healthcare professionals

Launch Details

According to the company's LODR filing:

GlobalSpace Technologies Ltd continues to combine deep domain expertise with cutting-edge technology, creating sustainable value for its clients and stakeholders in the pharmaceutical and healthcare sectors.

For more information about PATGPT and GlobalSpace Technologies Ltd, interested parties can visit the company's website at www.globalspace.in or contact them at Info@globalspace.in .